|
|
 |
|
Johnson & Johnson
|
Johnson & Johnson Vision Care, Inc. is a company committed to transforming the world's vision. Since our inception, we have strived to increase awareness of the importance of vision and vision care and to provide the world's most exceptional vision correction options. To that end, Johnson & Johnson Vision Care, Inc., through our passion for innovation and our unwavering commitment to the highest standards of quality, has become a world leader in vision care, providing a family of outstanding contact lens and spectacle products. Johnson & Johnson Vision Care, Inc. comprises two divisions that are fully committed to enhancing patients' lives and partnering with Eye Care Professionals. Vistakon, headquartered in Jacksonville, Florida, is the maker of ACUVUE?Brand Contact Lenses, the world leader in soft disposable contact lenses. The Spectacle Lens Group, which is headquartered in Roanoke, Virginia, manufactures the next generation of high tech multifocal spectacle lenses.
|
|
Please choose the following products of Johnson & Johnson
|
|
|
|
|
Page:1 2 |
|
|
|
Today's News about Johnson & Johnson |
Johnson & Johnson Is Reinventing The Party Drug Ketamine To Treat Depression
Until joining the company a few years ago, J&J neuroscience R&D head Husseini Manji led the mood and anxiety disorders program at the National Institutes of Health. While there, he helped run a program that led to one of the greatest breakthroughs in psychiatry in recent years: the knowledge that a brain receptor called the N-methyl- D-aspartate (NMDA) receptor played a key role in depression ...
J&J expects 10-plus new drug applications by 2017
Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday ...
Johnson & Johnson Pharmaceuticals Segment Poised to Continue Driving Growth with More than 10 Potential New Product ...
NEW BRUNSWICK, N.J., May 23, 2013 /PRNewswire/ -- At a meeting today with industry analysts, senior leaders from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced they anticipate ...
Johnson & Johnson says it will submit 10 new medicines for approval by 2017
J&J is targeting some of the biggest markets and diseases that currently have few treatment options in its growth plan
Johnson & Johnson (JNJ) Dividend Stock Analysis
By Dividends4Life. Read more » » Related Stocks: JNJ , ABBV , LLY , BMY ,
Johnson & Johnson forecasts 10 new drug applications by 2017
NEW BRUNSWICK — Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during a review of the health care giant's med
Johnson says no shave until Nats start hitting
WASHINGTON (AP) -- Davey Johnson says he's giving up his razor until the Washington Nationals find their bats.
Johnson & Johnson (DePuy) Stopping Production of All-Metal Hip Replacement Products
" The decision to stop selling the hips isn’t related to safety or effectiveness, and it isn’t a recall ." (Bloomberg News, 5/17, Cortez) This is the statement issued by an un-cited Johnson & Johnson spokesperson concerning its recent decision to stop production of all-metal replacement hips after August 31, 2013. (If you’re scheduled for a hip replacement this summer be sure your surgeon sees ...
Journalist and author Haynes Johnson dies at 81
WASHINGTON (AP) — Pioneering Washington journalist Haynes Johnson, who helped redefine political reporting, has died at age 81.
Johnson & Johnson to Submit 10 New Product Filings by 2017
Johnson & Johnson to Submit 10 New Product Filings by 2017
|
|
